Literature DB >> 22268494

Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms.

Dongyue Li1, Peng Zhan, Erik De Clercq, Xinyong Liu.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22268494     DOI: 10.1021/jm200990c

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  20 in total

1.  The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.

Authors:  Vigneshwaran Namasivayam; Murugesan Vanangamudi; Victor G Kramer; Sonali Kurup; Peng Zhan; Xinyong Liu; Jacob Kongsted; Siddappa N Byrareddy
Journal:  J Med Chem       Date:  2018-12-27       Impact factor: 7.446

2.  Bifunctional inhibition of human immunodeficiency virus type 1 reverse transcriptase: mechanism and proof-of-concept as a novel therapeutic design strategy.

Authors:  Christopher M Bailey; Todd J Sullivan; Pinar Iyidogan; Julian Tirado-Rives; Raymond Chung; Juliana Ruiz-Caro; Ebrahim Mohamed; William L Jorgensen; William Jorgensen; Roger Hunter; Karen S Anderson
Journal:  J Med Chem       Date:  2013-05-09       Impact factor: 7.446

3.  Effects of the protonation state in the interaction of an HIV-1 reverse transcriptase (RT) amino acid, Lys101, and a non nucleoside RT inhibitor, GW420867X.

Authors:  Sérgio E Galembeck; F Matthias Bickelhaupt; Célia Fonseca Guerra; Eduardo Galembeck
Journal:  J Mol Model       Date:  2014-06-26       Impact factor: 1.810

4.  Novel Cyclopropyl-Indole Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors.

Authors:  Mohammad Hassam; Adriaan E Basson; Dennis C Liotta; Lynn Morris; Willem A L van Otterlo; Stephen C Pelly
Journal:  ACS Med Chem Lett       Date:  2012-05-02       Impact factor: 4.345

5.  Discovery of Phenylaminopyridine Derivatives as Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.

Authors:  Junwon Kim; Doohyun Lee; Changmin Park; Wonyoung So; Mina Jo; Taedong Ok; Jeongjin Kwon; Sunju Kong; Suyeon Jo; Youngmi Kim; Jihyun Choi; Hyoung Cheul Kim; Yoonae Ko; Inhee Choi; Youngsam Park; Jaewan Yoon; Moon Kyeong Ju; Junghwan Kim; Sung-Jun Han; Tae-Hee Kim; Jonathan Cechetto; Jiyoun Nam; Peter Sommer; Michel Liuzzi; Jinhwa Lee; Zaesung No
Journal:  ACS Med Chem Lett       Date:  2012-07-11       Impact factor: 4.345

6.  Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.

Authors:  Dongwei Kang; Zhao Wang; Heng Zhang; Gaochan Wu; Tong Zhao; Zhongxia Zhou; Zhipeng Huo; Boshi Huang; Da Feng; Xiao Ding; Jian Zhang; Xiaofang Zuo; Lanlan Jing; Wei Luo; Samuel Guma; Dirk Daelemans; Erik De Clercq; Christophe Pannecouque; Peng Zhan; Xinyong Liu
Journal:  ACS Med Chem Lett       Date:  2018-03-01       Impact factor: 4.345

7.  Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the "NNRTI Adjacent" Binding Site.

Authors:  Zhipeng Huo; Heng Zhang; Dongwei Kang; Zhongxia Zhou; Gaochan Wu; Samuel Desta; Xiaofang Zuo; Zhao Wang; Lanlan Jing; Xiao Ding; Dirk Daelemans; Erik De Clercq; Christophe Pannecouque; Peng Zhan; Xinyong Liu
Journal:  ACS Med Chem Lett       Date:  2018-02-27       Impact factor: 4.345

Review 8.  Recent findings on the mechanisms involved in tenofovir resistance.

Authors:  Pinar Iyidogan; Karen S Anderson
Journal:  Antivir Chem Chemother       Date:  2014-12-16

9.  Discovery of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP.

Authors:  Dongwei Kang; Xiao Ding; Gaochan Wu; Zhipeng Huo; Zhongxia Zhou; Tong Zhao; Da Feng; Zhao Wang; Ye Tian; Dirk Daelemans; Erik De Clercq; Christophe Pannecouque; Peng Zhan; Xinyong Liu
Journal:  ACS Med Chem Lett       Date:  2017-10-19       Impact factor: 4.345

10.  Structural Insights to Human Immunodeficiency Virus (HIV-1) Targets and Their Inhibition.

Authors:  Murugesan Vanangamudi; Pramod C Nair; S E Maida Engels; Senthilkumar Palaniappan; Vigneshwaran Namasivayam
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.